Aged 25-80 at screening. Subjects older than 80 will be allowed at the discretion of the PI.
Ambulatory (defined as able to ambulate at least 10 meters, with or without assistance).
Clinical Diagnosis of PD based on the United Kingdom Brain Bank diagnostic criteria for PD.
At least 8 micturitions per 24 hours and
At least 3 urgency episodes per 3-day diary.
A MoCA score between 19 and 28 (inclusive) at screening. For those on cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29 (inclusive) at screening.
Provide informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.
Be cognitively capable, in the opinion of investigator, to understand and provide such informed consent.
Be cognitively capable to complete the required questionnaires and assessments, OR have a care partner who is willing and capable to assist them in the completion of these tasks.
Be on a stable regimen of antiparkinson's medications at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.
If taking cognitive enhancers (donepezil, rivastigmine, memantine, galantamine), must be on stable dose at least 30 days prior to screening, and be expected to remain on a stable dose for the duration of the study.

NCT02536976_inc_T1
Person
Aged
NCT02536976_inc_T2
Value
25-80
NCT02536976_inc_T4
Person
Ambulatory
NCT02536976_inc_T6
Condition
PD
NCT02536976_inc_T7
Measurement
United Kingdom Brain Bank diagnostic criteria
NCT02536976_inc_T8
Condition
micturitions
NCT02536976_inc_T9
Multiplier
least 8 mi  24 hours a
NCT02536976_inc_T10
Condition
urgency episodes
NCT02536976_inc_T11
Multiplier
east 3 urg 3-day diary.
A M
NCT02536976_inc_T12
Measurement
MoCA score
NCT02536976_inc_T13
Value
between 19 and 28
NCT02536976_inc_T14
Procedure
cognitive enhancers
NCT02536976_inc_T15
Drug
donepezil
NCT02536976_inc_T16
Drug
rivastigmine
NCT02536976_inc_T17
Drug
memantine
NCT02536976_inc_T18
Drug
galantamine
NCT02536976_inc_T19
Measurement
MoCA score
NCT02536976_inc_T20
Value
between 19 and 29
NCT02536976_inc_T21
Scope
donepezil, rivastigmine, memantine, galantamine
NCT02536976_inc_T22
Scope
cognitive enhancers (donepezil, rivastigmine, memantine, galantamine) a MoCA score between 19 and 29
NCT02536976_inc_T26
Drug
antiparkinson's medications
NCT02536976_inc_T27
Temporal
at least 30 days prior to screening
NCT02536976_inc_T28
Reference_point
screening
NCT02536976_inc_T29
Procedure
cognitive enhancers
NCT02536976_inc_T30
Drug
donepezil
NCT02536976_inc_T31
Drug
rivastigmine
NCT02536976_inc_T32
Drug
memantine
NCT02536976_inc_T33
Drug
galantamine
NCT02536976_inc_T34
Scope
donepezil, rivastigmine, memantine, galantamine
NCT02536976_inc_T35
Qualifier
stable dose
NCT02536976_inc_T36
Temporal
at least 30 days prior to screening
NCT02536976_inc_T37
Reference_point
screening